Ponatinib Package Insert

HIGHLIGHTS OF PRESCRIBING INFORMATION ABRAXANE
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine. 2 DOSAGE AND ADMINISTRATION . 2.1 Metastatic Breast Cancer . ... Fetch This Document

Cobimetinib - Wikipedia
Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech . It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. ... Read Article

ALPROLIX Package Insert - Food And Drug Administration
Provided in the ALPROLIX package. 8. With one hand, hold the diluent syringe by the ridged part directly under the cap, with the 10. With the vial sitting on a flat surface, insert the tip of ... Doc Viewer

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
FULL PRESCRIBING INFORMATION WARNING: QT PROLONGATION AND SUDDEN DEATHS Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies (5.2). ... Access Full Source

As Clinically Indicated. Interrupt Iclusig For ANC <1000/mm
HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG ® (ponatinib) tablets, for oral use Initial U.S. Approval: 2012 . WARNING: ARTERIAL OCCLUSION, VENOUS THROMBOEMBOLISM, HEART FAILURE, and HEPATOTOXICITY ... View Document

Ponatinib (Iclusig)
Ponatinib is the only TKI with activity against the T315I mutation. Current evidence also supports consideration of use in patients who have not responded to two or (for more detailed information refer to the product package insert) ... Access This Document

*Sections Or Subsections Omitted From The Full Prescribing ...
*Sections or subsections omitted from the Full Prescribing Information are not listed. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. ERIVEDGE can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. ERIVEDGE is embryotoxic, fetotoxic, and teratogenic in animals. ... Retrieve Document

Lestaurtinib - Wikipedia
Lestaurtinib (rINN, codenamed CEP-701) is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION Patients At Risk Of ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TARCEVA® safely and effectively. See full prescribing information for TARCEVA. TARCEVA (erlotinib) tablets, for oral use Initial U.S. Approval: 2004 -----RECENT MAJOR CHANGES----- ... Fetch Full Source

Package Leaflet: Information For The Patient Iclusig 15 Mg ...
Package leaflet: Information for the patient . Iclusig 15 mg film-coated tablets . Iclusig 30 mg film-coated tablets . Iclusig 45 mg film-coated tablets . ponatinib . This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. ... View This Document

ZOCOR(simvastatin) Tablets - Merck.com
FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events 1.2 Hyperlipidemia 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) 1.4 Limitations of Use 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosing 2.2 Restricted Dosing for 80mg ... Access Doc

ICLUSIG (ponatinib) Tablets
ICLUSIG ® (ponatinib) tablets for oral use Initial U.S. Approval: 2012 WARNING: ARTERIAL THROMBOSIS and HEPATOTOXICITY . See full prescribing information for complete boxed warning . ... Access This Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - Folotyn
Dosage and Administration (2.1, 2.2, 2.3) 5/2012 Warnings and Precautions, Risk of Increased Toxicity in the Presence of Impaired Renal Function (5.6) 5/2012 -----INDICATIONS AND USAGE----- FOLOTYN is a folate analog metabolic inhibitor indicated for the treatment of ... Content Retrieval

SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. 2 DOSAGE AND ADMINISTRATION . ... Fetch Document

Simple Determination Of Plasma Ponatinib Concentration Using HPLC
Been recommended in the ponatinib package insert.10) How-ever, the relationship between ponatinib blood concentration and these events is unknown. Several analytical methods using liquid chromatography-tandem mass spectrometry (LC-MS/MS) have been reported for the quantitative determination of ponatinib in human plas- ... Fetch Full Source

Ponatinib: An Oral Tyrosine Kinase Inhibitor For The ...
Ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract]. Presented at the American Society of Clinical Oncology Annual Meeting, June 1, 2012, Chicago, IL. Abstract 6503. 6) Iclusig (ponatinib)[package insert]. Cambridge , MA: ARIAD Pharmaceuticals, Inc.; December 2012. ... Fetch Doc

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ... Read Content

Denileukin Diftitox - Wikipedia
Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION - Merck.com
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZOLINZA® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information ... View This Document